Relative efficacy of selective COX-2 inhibitors compared with over-the-counter ibuprofen

Area of Science:

• Pharmacology
• Pain Management
• Inflammation Research

Background:

• Non-steroidal anti-inflammatory drugs (NSAIDs) target cyclo-oxygenase (COX) enzymes.
• COX-1 inhibition causes gastrointestinal side effects, while COX-2 inhibition offers therapeutic benefits.
• Selective COX-2 inhibitors show promise but their analgesic efficacy and safety at higher doses are uncertain.

Purpose of the Study:

• To compare the analgesic efficacy and onset of action of ibuprofen (non-selective NSAID) and celecoxib (COX-2 inhibitor).
• To investigate the role of COX-1 and COX-2 inhibition in pain management.
• To explore the impact of early nociception on later hyperalgesia.

Main Methods:

• Experimental pain model comparing ibuprofen and celecoxib.
• Measurement of prostaglandin E2 concentrations post-administration.
• Assessment of pain reduction compared to placebo.

Main Results:

• Ibuprofen rapidly suppressed prostaglandin E2, while celecoxib's effect was delayed.
• Both ibuprofen and celecoxib reduced pain significantly compared to placebo.
• Celecoxib demonstrated a slower onset of analgesic action than ibuprofen.

Conclusions:

• Simultaneous inhibition of COX-1 and COX-2 enhances analgesia.
• Ibuprofen offers rapid pain relief for acute pain with good short-term tolerability.
• Further research is needed to clarify the role of COX-2 inhibitors in analgesia, especially at higher doses.